|
PCNA expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.22250000123003E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.86559995124713E-09 |
| Normal-vs-Stage2 |
1.225680E-02 |
| Normal-vs-Stage3 |
3.00440000000624E-06 |
| Normal-vs-Stage4 |
1.405770E-02 |
| Stage1-vs-Stage2 |
1.477830E-02 |
| Stage1-vs-Stage3 |
7.694400E-01 |
| Stage1-vs-Stage4 |
2.074000E-01 |
| Stage2-vs-Stage3 |
6.550200E-02 |
| Stage2-vs-Stage4 |
5.742800E-01 |
| Stage3-vs-Stage4 |
3.662200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.48550005419202E-09 |
| Normal-vs-AfricanAmerican |
2.901600E-02 |
| Normal-vs-Asian |
3.19689999994655E-06 |
| Caucasian-vs-AfricanAmerican |
7.099400E-01 |
| Caucasian-vs-Asian |
6.425400E-01 |
| AfricanAmerican-vs-Asian |
5.080200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.433900E-04 |
| Normal-vs-Female |
3.2765999913309E-09 |
| Male-vs-Female |
1.204360E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.0753000408198E-09 |
| Normal-vs-Age(41-60Yrs) |
2.61109999999398E-06 |
| Normal-vs-Age(61-80Yrs) |
8.049600E-04 |
| Normal-vs-Age(81-100Yrs) |
1.213370E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.115950E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.707900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.040200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.539600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.989800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.137400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.686500E-02 |
| Classical-VS-Follicular |
1.20810000003857E-06 |
| Classical-VS-Other |
5.761200E-01 |
| Classical-VS-Normal |
1.6344003928026E-10 |
| Tall-VS-Follicular |
1.65444999999931E-05 |
| Tall-VS-Other |
1.554170E-01 |
| Tall-VS-Normal |
1.89280000006953E-07 |
| Follicular-VS-Other |
3.293600E-01 |
| Follicular-VS-Normal |
2.779800E-01 |
| Other-VS-Normal |
2.394200E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.57160000002765E-06 |
| Normal-vs-N1 |
3.119600E-03 |
| N0-vs-N1 |
9.464600E-01 |
|
|
